JP2008525409A5 - - Google Patents

Download PDF

Info

Publication number
JP2008525409A5
JP2008525409A5 JP2007547651A JP2007547651A JP2008525409A5 JP 2008525409 A5 JP2008525409 A5 JP 2008525409A5 JP 2007547651 A JP2007547651 A JP 2007547651A JP 2007547651 A JP2007547651 A JP 2007547651A JP 2008525409 A5 JP2008525409 A5 JP 2008525409A5
Authority
JP
Japan
Prior art keywords
independently
och
nme
ome
ipr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2007547651A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008525409A (ja
Filing date
Publication date
Priority claimed from GBGB0428082.2A external-priority patent/GB0428082D0/en
Application filed filed Critical
Publication of JP2008525409A publication Critical patent/JP2008525409A/ja
Publication of JP2008525409A5 publication Critical patent/JP2008525409A5/ja
Withdrawn legal-status Critical Current

Links

JP2007547651A 2004-12-22 2005-12-22 治療用化合物としてのピラジンおよびピリジンならびにその誘導体 Withdrawn JP2008525409A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US63789204P 2004-12-22 2004-12-22
GBGB0428082.2A GB0428082D0 (en) 2004-12-22 2004-12-22 Therapeutic compounds
PCT/GB2005/005011 WO2006067466A2 (en) 2004-12-22 2005-12-22 Pyrazines and pyridines and derivatives thereof as therapeutic compounds

Publications (2)

Publication Number Publication Date
JP2008525409A JP2008525409A (ja) 2008-07-17
JP2008525409A5 true JP2008525409A5 (cg-RX-API-DMAC7.html) 2009-02-12

Family

ID=34113050

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007547651A Withdrawn JP2008525409A (ja) 2004-12-22 2005-12-22 治療用化合物としてのピラジンおよびピリジンならびにその誘導体

Country Status (11)

Country Link
US (1) US7737152B2 (cg-RX-API-DMAC7.html)
EP (1) EP1831184B1 (cg-RX-API-DMAC7.html)
JP (1) JP2008525409A (cg-RX-API-DMAC7.html)
AT (1) ATE497951T1 (cg-RX-API-DMAC7.html)
AU (1) AU2005317890A1 (cg-RX-API-DMAC7.html)
CA (1) CA2591208A1 (cg-RX-API-DMAC7.html)
DE (1) DE602005026321D1 (cg-RX-API-DMAC7.html)
GB (1) GB0428082D0 (cg-RX-API-DMAC7.html)
NZ (1) NZ556125A (cg-RX-API-DMAC7.html)
WO (1) WO2006067466A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA200705979B (cg-RX-API-DMAC7.html)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL162210A0 (en) * 2001-11-28 2005-11-20 Btg Int Ltd Preventives or remedies for alzheimer's disease oramyloid protein fibrosis inhibitors containing ni trogen-containing heteroaryl
AU2006223409B2 (en) * 2005-03-10 2011-07-21 Gilead Connecticut, Inc. Certain substituted amides, method of making, and method of use thereof
DE602007004618D1 (de) * 2006-06-22 2010-03-18 Biovitrum Ab Publ Pyridin- und pyrazinderivate als mnk-kinaseinhibitoren
JP2008081492A (ja) 2006-08-31 2008-04-10 Banyu Pharmaceut Co Ltd オーロラa選択的阻害作用を有する新規アミノピリジン誘導体
EP1992344A1 (en) * 2007-05-18 2008-11-19 Institut Curie P38 alpha as a therapeutic target in pathologies linked to FGFR3 mutation
EP2203436A1 (en) * 2007-09-17 2010-07-07 Neurosearch A/S Pyrazine derivatives and their use as potassium channel modulators
AU2014253528B2 (en) * 2007-12-19 2016-07-21 Cancer Research Technology Limited Pyrido[2,3-b]pyrazine-8-substituted compounds and their use
NZ586418A (en) * 2007-12-19 2012-09-28 Cancer Rec Tech Ltd Pyrido[2,3-b]pyrazine-8-substituted compounds and their use
US8436171B2 (en) * 2008-02-01 2013-05-07 Akinion Pharmaceuticals Ab Amino substituted pyrazines as inhibitors or protein kinases
GB0807609D0 (en) 2008-04-25 2008-06-04 Cancer Rec Tech Ltd Therapeutic compounds and their use
DK2531502T3 (da) 2010-02-01 2014-05-19 Cancer Rec Tech Ltd 1-(5-tert-butyl-2-phenyl-2h-pyrazol-3-yl)-3-[2-fluoro-4-(1-methyl-2-oxo-2,3-dihydro-1h-imidazo[4,5-b]pyridin-7-yloxy)-phenyl]-urea og associerede forbindelser og ders anvendelse i terapi
JP5744021B2 (ja) 2010-06-30 2015-07-01 富士フイルム株式会社 新規なニコチンアミド誘導体またはその塩
CA2856812A1 (en) * 2010-11-28 2012-05-31 Metasignal Therapeutics Inc. Carbonic anhydrase inhibitors with antimetastatic activity
ES2699965T3 (es) 2011-03-10 2019-02-13 Provectus Pharmatech Inc Una combinación de rosa de bengala y anticuerpo anti-CTLA4 para su uso en el tratamiento del cáncer
US10713634B1 (en) 2011-05-18 2020-07-14 Stamps.Com Inc. Systems and methods using mobile communication handsets for providing postage
MX2015008010A (es) * 2012-12-20 2016-04-26 qing-bin Lu Compuestos radiosensabilizadores para usarse en combinacion con radiacion.
KR102307387B1 (ko) * 2013-10-08 2021-09-30 큉-빈 루 표적화된 화학요법에 사용하기 위한 비­백금­기반 항암 화합물
GB201320729D0 (en) 2013-11-25 2014-01-08 Cancer Rec Tech Ltd Therapeutic compounds and their use
GB201320732D0 (en) 2013-11-25 2014-01-08 Cancer Rec Tech Ltd Methods of chemical synthesis
KR102218333B1 (ko) 2016-06-07 2021-02-22 자코바이오 파마슈티칼스 컴퍼니 리미티드 Shp2 억제제로서 유용한 신규한 헤테로환형 유도체
SG11201908820VA (en) 2017-03-23 2019-10-30 Jacobio Pharmaceuticals Co Ltd Novel heterocyclic derivatives useful as shp2 inhibitors
CN112839935A (zh) 2018-09-26 2021-05-25 北京加科思新药研发有限公司 可用作shp2抑制剂的新型杂环衍生物
BR112021013924A2 (pt) 2019-01-18 2021-09-21 Astrazeneca Ab Inibidores de pcsk9 e métodos de uso do mesmo
WO2020150473A2 (en) 2019-01-18 2020-07-23 Dogma Therapeutics, Inc. Pcsk9 inhibitors and methods of use thereof
CN111499613B (zh) * 2019-01-31 2023-05-12 浙江海正药业股份有限公司 N-甲酰胺衍生物、其制备方法及其在医药上的用途
JP2022533939A (ja) * 2019-05-17 2022-07-27 キネート バイオファーマ インク. 線維芽細胞増殖因子受容体キナーゼの阻害剤
JP7319395B2 (ja) * 2019-06-14 2023-08-01 ディスアーム セラピューティクス, インコーポレイテッド Sarm1の阻害剤
EP4143167B1 (en) 2020-04-28 2024-05-15 Basf Se Pesticidal compounds
CA3184471A1 (en) 2020-05-27 2021-12-02 The Penn State Research Foundation Antibacterial compounds
CN116057045B (zh) 2020-06-05 2026-06-09 金耐特生物制药公司 成纤维细胞生长因子受体激酶抑制剂
WO2022098808A1 (en) * 2020-11-05 2022-05-12 Aria Pharmaceuticals, Inc. Therapeutic agents for treating hepatocellular carcinoma
CN116272897B (zh) * 2023-02-27 2024-08-27 中国检验检疫科学研究院 富集香豆素类化合物的磁性纳米粒及其制备方法和应用

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4666828A (en) * 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US4683202A (en) * 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) * 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
US5272057A (en) * 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
US5192659A (en) * 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
US5643755A (en) * 1994-10-07 1997-07-01 Regeneron Pharmaceuticals Inc. Nucleic acid encoding tie-2 ligand
US5879672A (en) * 1994-10-07 1999-03-09 Regeneron Pharmaceuticals, Inc. Tie-2 ligand 1
EP0783572B1 (en) * 1994-09-22 2005-04-27 Licentia Ltd. Promoter for the receptor tyrosine kinase, tie
EP0813525B9 (en) * 1995-03-10 2004-02-04 Berlex Laboratories, Inc. Benzamidine derivatives their preparation and their use as anti-coagulants
US5691364A (en) * 1995-03-10 1997-11-25 Berlex Laboratories, Inc. Benzamidine derivatives and their use as anti-coagulants
US6218529B1 (en) * 1995-07-31 2001-04-17 Urocor, Inc. Biomarkers and targets for diagnosis, prognosis and management of prostate, breast and bladder cancer
CA2744096C (en) * 1996-07-31 2013-07-30 Laboratory Corporation Of America Holdings Biomarkers and targets for diagnosis, prognosis and management of prostate disease
AU7585598A (en) 1997-05-23 1998-12-11 Bayer Corporation Raf kinase inhibitors
US6030831A (en) * 1997-09-19 2000-02-29 Genetech, Inc. Tie ligand homologues
MXPA02002559A (es) * 1999-09-10 2002-07-30 Merck & Co Inc Inhibidores de tirosina cinasa.
DK1330452T3 (da) * 2000-09-20 2009-03-16 Ortho Mcneil Janssen Pharm Pyrazinderivater som modulatorer af tyrosinkinaser
WO2002060492A1 (en) 2001-01-30 2002-08-08 Cytopia Pty Ltd Methods of inhibiting kinases
CA2463563A1 (en) 2001-10-12 2003-04-17 Irm Llc Kinase inhibitor scaffolds and methods for their preparation
IL161662A0 (en) 2001-11-01 2004-09-27 Janssen Pharmaceutica Nv Heteroaryl amines as glycogen synthase kinase 3 beta inhibitors (gsk3 inhibitors)
EP1456364B1 (en) 2001-12-21 2011-03-23 The Wellcome Trust Mutations in the b-raf gene
CA2486183C (en) * 2002-05-23 2012-01-10 Cytopia Pty Ltd. Protein kinase inhibitors
AU2002953255A0 (en) 2002-12-11 2003-01-02 Cytopia Research Pty Ltd Protein kinase inhibitors
GB2400101A (en) * 2003-03-28 2004-10-06 Biofocus Discovery Ltd Compounds capable of binding to the active site of protein kinases
EP1644365A2 (en) * 2003-07-02 2006-04-12 Biofocus Discovery Ltd Pyrazine and pyridine derivatives as rho kinase inhibitors

Similar Documents

Publication Publication Date Title
RU2442778C9 (ru) Новые соединения, действующие как ингибиторы erk
JP2015535831A5 (cg-RX-API-DMAC7.html)
JP2004511462A5 (cg-RX-API-DMAC7.html)
JP2005517675A5 (cg-RX-API-DMAC7.html)
JP2020503340A5 (cg-RX-API-DMAC7.html)
RU2009130599A (ru) Лекарственные препараты для лечения рака
UY38742A (es) Compuestos de 2,3,5-pyrazolo[1,5-a]pirimidina trisustituida
EP4473980A3 (en) Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of psma-expressing cancers
ES2173154T3 (es) Compuestos de naftilo, intermedios, procedimientos y composiciones de los mismos.
JP2005523922A5 (cg-RX-API-DMAC7.html)
JP2025513882A5 (cg-RX-API-DMAC7.html)
JP2019514955A5 (cg-RX-API-DMAC7.html)
JP2019515643A5 (cg-RX-API-DMAC7.html)
RU2006139005A (ru) Применение производных 9н-пурин-2, 6-диамина для лечения пролиферативных заболеваний и новые производные 9н-пурин-2, 6-диамина
JP2005511556A5 (cg-RX-API-DMAC7.html)
JP2007525494A5 (cg-RX-API-DMAC7.html)
AU2007290490A1 (en) Combination with bis(thiohydrazide amides) for treating cancer
JP2014502599A5 (cg-RX-API-DMAC7.html)
CN116139125A (zh) 联合治疗
RU2007105233A (ru) Производные порфирина и их применение в фотонно-активационной терапии
JP2024502175A5 (cg-RX-API-DMAC7.html)
JP2023509944A5 (cg-RX-API-DMAC7.html)
WO2017190107A1 (en) Sigma receptor binders
CA2321149A1 (en) Antitumor agents
CA2519110A1 (fr) Derives du benzenesulfonamide, leur procede de preparation et leur utilisation dans le traitement de la douleur